MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its licensee Janssen Research & Development, LLC (Janssen) has reported positive results from a clinical phase 3 study examining guselkumab, a fully human antibody intended to target IL-23 identified from MorphoSys's HuCAL antibody library, in 837 patients with moderate to severe plaque psoriasis ("VOYAGE 1" study).
Janssen stated in a press release issued today that "new phase 3 data show significant efficacy versus placebo and superiority of guselkumab versus Humira® in treatment of moderate to severe plaque psoriasis" and that guselkumab "demonstrates significant efficacy compared with tumor necrosis factor blocker Humira® across all major study endpoints through 48 weeks of treatment". According to Janssen, the two co-primary endpoints of the study were met: Primary endpoints included improving signs and symptoms of psoriasis, while delivering clear or almost clear skin (IGA 0 or 1 and PASI 90) at week 16, in patients receiving guselkumab compared to placebo. In addition, according to Janssen, all major secondary endpoints achieved statistical significance in comparisons of guselkumab versus Humira®.
Janssen presented the data from the "VOYAGE 1" study today in a late breaking session at the 25th congress of the European Academy of Dermatology and Venereology (EADV) in Vienna, Austria. The randomized, double-blind, placebo- and active-comparator-controlled study evaluated guselkumab, in comparison to placebo and active comparator adalimumab (Humira®), in the treatment of moderate to severe plaque psoriasis.
END OF AD HOC ANNOUNCEMENT
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.
Humira® is a registered trademarks of AbbVie Inc.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Associate Director Corporate Communications & IR
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404